Creating a new generation of small molecule protease inhibitors

Slide 1

KalVista is a pharmaceutical company focused on the discovery, development and commercialization of small molecule protease inhibitors as new treatments for diseases with significant unmet needs.

Slide 2

KalVista is developing plasma kallikrein inhibitors for the treatment of hereditary angioedema (HAE) and diabetic macular edema (DME); indications where excessive plasma kallikrein activity is implicated, but where there remains substantial unmet clinical need.

Slide 3

KalVista continues to investigate additional proteases as potential therapeutic targets to fully exploit its research expertise and expand its portfolio.

Slide 4

The Company features an R&D team with an established track record in the pharmaceutical development of small molecule protease inhibitors, world-leading expertise in the role of plasma kallikrein in disease, and a management team with proven experience in bringing small molecules through the clinic to commercialization.

News

KalVista Pharmaceuticals to Present at Jefferies Healthcare Conference

1 June 2017 Read more...

KalVista Pharmaceuticals to Recognize HAE Day 2017

15 May 2017 Read more...